论文部分内容阅读
慢性乙型肝炎是全世界严重危害人类健康的主要传染病之一,全球每年死于慢乙肝患者大约12 0万人,单一的α-干扰素治疗仅可使2 5 % - 40 %慢乙肝获得疗效[1] ,泛昔洛韦和α-干扰素联合治疗效果明显[2 ] ,为此我们在二联的基础上加用胸腺肽联合治疗慢性乙型肝炎,并与二联治疗进行?
Chronic hepatitis B is one of the major infectious diseases that endanger human health in the world. Approximately 120 million people die of chronic hepatitis B virus each year in the world. A single interferon-alpha treatment can only get 25% -40% of chronic hepatitis B Efficacy [1], famciclovir and interferon-alpha combination treatment effect is obvious [2], therefore we add thymosin combined treatment of chronic hepatitis B on the basis of the two, and with the two-way treatment?